retatrutide trial results today Eli Lilly and Company's triple agonist, retatrutide, successful in two additional phase 3 obesity trials, delivering significant improvements in weight and A1C Retatrutide: Phase 3 Results (Up
Pay in 4 interest-free payments of $7.10 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4































